methylphenidate and Acute Confusional Senile Dementia

methylphenidate has been researched along with Acute Confusional Senile Dementia in 34 studies

Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.

Research

Studies (34)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Neuropsychiatric Inventory (NPI)

"Mean difference in change from baseline to 6 months in the NPI apathy subscale scores as administered by certified personnel to the study caregiver.~SEVERITY is graded 1 to 3 and FREQUENCY is graded 1 to 4. The overall score for the domain is the product of the severity and frequency which ranges from 1 to 12 with higher scores indicating more apathy." (NCT02346201)
Timeframe: baseline to 6 months

Percentage of Participants With Change in Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (CGIC)

"Percentage of individuals improving on Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (CGIC) from baseline to 6 months; the CGIC is a 7-point Likert scale used to rate each patient with the following scores: marked worsening(7), moderate worsening (6), minimal worsening(5), no change(4), minimal improvement(3), moderate improvement(2), marked improvement(1). Ratings were based on an interview with the caregiver and an examination of the patient. The CGIC requires the clinician to consider a number of aspects of apathy, such as level of initiative, level of interest, and emotional engagement. Reported data is the percentage of participants with minimal/moderate/marked improvement." (NCT02346201)
Timeframe: Baseline to month 6

Apathy Evaluation Scale Score at 12 Weeks

The Apathy Evaluation Scale (AES) has been specifically developed to assess apathy and discriminate it from depression. This 18 item scale with score ranging from 18 to 72, assesses apathy in behavioral, cognitive and emotional domains over the previous four weeks. Higher scores indicate worsening apathy. (NCT00495820)
Timeframe: At 12 weeks

Clinical Global Impression

The Clinical Global Impression scale is an observational scale of global evaluation, which assesses the change in degree of illness in relation to the original assessment. The severity sub-scale reported below ranges from 1-7 wherein higher scores indicate worsening severity of illness. (NCT00495820)
Timeframe: At 12 weeks

Mini-mental State Examination (MMSE) at 12 Weeks

Mini-mental State Examination (MMSE) is a commonly used screening measure for cognition with questions pertaining to orientation, registration, recall, visuo-spatial construction, attention span etc. Score on MMSE ranges from 0-30, higher scores indicating improving cognition (NCT00495820)
Timeframe: At 12 weeks

Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change

"Proportion of individuals improving on Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (CGIC) from baseline to 6 weeks; the CGIC is a 7-point Likert scale used to rate each patient with the following scores: marked worsening(7), moderate worsening (6), minimal worsening(5), no change(4), minimal improvement(3), moderate improvement(2), marked improvement(1). Ratings were based on an interview with the caregiver and an examination of the patient. The CGIC requires the clinician to consider a number of aspects of apathy, such as level of initiative, level of interest, and emotional engagement." (NCT01117181)
Timeframe: baseline to 6 weeks

Apathy Evaluation Scale (AES)

Change in score of Apathy Evaluation Scale from baseline to 6 weeks; the minimum score is 18; the maximum score is 72. Higher scores indicate more severe apathy. (NCT01117181)
Timeframe: baseline to 6 weeks

Digit Span

Change in Digit Span from baseline to 6 weeks. The Wechsler Adult Intelligence Scale - Revised Digit Span is used to assess auditory attention and working memory. Both forward and backward span is assessed. Both tests consist of six number sequences that the psychometrist reads aloud one at a time. After each sequence is read, the participant must repeat the digits back in the same (forward) or reverse (backward) order. Scores range from 0 to 16, with higher numbers indicate better functioning. (NCT01117181)
Timeframe: baseline and 6 weeks

Electrocardiogram (ECG)

Abnormal electrocardiogram results at 6 weeks (NCT01117181)
Timeframe: 6 weeks

Mini-Mental State Exam (MMSE)

Change in Mini-Mental State Exam score from baseline to 6 weeks; this cognitive test estimates of dementia severity. Domains included orientation, memory, working memory, naming, following verbal and written commands, spontaneously writing a sentence, and copying two overlapping pentagons. The minimum MMSE score is 0; the maximum MMSE score is 30. Lower MMSE scores indicate more severe cognitive impairment. (NCT01117181)
Timeframe: baseline and 6 weeks

Neuropsychiatric Inventory (NPI): Apathy Subscale

Change from baseline to 6 weeks in neuropsychiatric symptoms in apathy subscore. Frequency (ranges from 1=occasionally, less than once/week to 4 = very frequently, once or more/day or continuously) and severity (1=mild, 2=moderate, 3=severe) scales are scored based on responses from an informed caregiver involved in the patient's life. To obtain the NPI score, the severity score is multiplied by the frequency score. Range is 0 to 12. Larger numbers indicate more severe behavioral disturbance. (NCT01117181)
Timeframe: baseline to week 6

Vital Status

vital status as measured by death (NCT01117181)
Timeframe: vital status at 6 weeks

Electrolytes

Percent of participants with abnormal electrolyte values at 6 weeks as assessed by local laboratory (NCT01117181)
Timeframe: 6 weeks

Reviews

8 reviews available for methylphenidate and Acute Confusional Senile Dementia

Trials

9 trials available for methylphenidate and Acute Confusional Senile Dementia

Other Studies

17 other studies available for methylphenidate and Acute Confusional Senile Dementia